Metabolic Syndrome After Kidney Transplantation
Abstract Background Metabolic syndrome (MS) includes some risk factors for development of diabetes and cardiovascular disease, obesity (BMI > 30), high triglycerides, low HDL cholesterol, hypertension and impaired glucose tolerance. Following the definition of the Adult Treatment Panel III criter...
Gespeichert in:
Veröffentlicht in: | Transplantation proceedings 2007-07, Vol.39 (6), p.1843-1846 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1846 |
---|---|
container_issue | 6 |
container_start_page | 1843 |
container_title | Transplantation proceedings |
container_volume | 39 |
creator | Faenza, A Fuga, G Nardo, B Donati, G Cianciolo, G Scolari, M.P Stefoni, S |
description | Abstract Background Metabolic syndrome (MS) includes some risk factors for development of diabetes and cardiovascular disease, obesity (BMI > 30), high triglycerides, low HDL cholesterol, hypertension and impaired glucose tolerance. Following the definition of the Adult Treatment Panel III criteria, a diagnosis of MS was established when 3 or more factors were present. In renal transplan patients MS has been reported to negatively influence both patient and graft survivals. The present study sought to verify the effect of MS among our cases. Methods 298 cadaveric renal transplant recipients operated between January 1, 1996 and December 31, 2001 with absence of diabetes before transplantation, stable renal function 1 year posttransplantation and at least 4 years follow up were retrospectively evaluated from the end of the first post-operative year. Results 50 patients out of 298 (16,7%) had MS at the beginning of the study, including 37 of them with 3 and 13 with 4 risk factors. Only one patient with MS died of cardiovascular disease. Graft failure was observed in 23.5% MS patients versus 9,7% patients without the Syndrome (p:n.s.) Only Creatinine and the incidence of Cardiovascular Diseases at 4 years were statistically higher in MS patients ( P < .001). Conclusions These results suggested that MS is a risk factor for increasing CVD morbidity and decreased graft function, but early treatment of risk factors as soon as they become apparent can limit the adverse effects on patient and graft survival. |
doi_str_mv | 10.1016/j.transproceed.2007.07.019 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68156060</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134507008081</els_id><sourcerecordid>68156060</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-2090d10788af333569b5c130f8da4e31756d2fb4ae5c6bcedb974c0b0ff462453</originalsourceid><addsrcrecordid>eNqNkd9r2zAQx8VoWdOs_8IIg-7N6Z0ky3YfBiHrL9qxh7bPQpZPoMyxM8kp5L-vvISu7GlwIMR97r5332PsC8IcAdXFaj4E08VN6C1RM-cAxXwMrD6wCZaFyLji4ohNACRmKGR-wk5jXEH6cyk-shMsVJWYasIuftBg6r71dva465rQr2m2cAOF2b1vOtrNnv5ItaYbzOD77hM7dqaNdHZ4p-z5-uppeZs9_Ly5Wy4eMiuVGDIOFTQIRVkaJ4TIVVXnFgW4sjGSBBa5arirpaHcqtpSU1eFtFCDc1JxmYsp-7rvm7b8vaU46LWPlto0CPXbqFWJuQIFCbzcgzb0MQZyehP82oSdRtCjXXql39ulR7v0GFil4s8HlW29Trm30oM_CTg_ACZa07rUyPr4l6uAIypM3Pc9R8mTF09BR-upS4v5QHbQTe__b55v_7Sxre98Uv5FO4qrfhu65LpGHbkG_TgeeLwvFAAllCheAee3o6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68156060</pqid></control><display><type>article</type><title>Metabolic Syndrome After Kidney Transplantation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Faenza, A ; Fuga, G ; Nardo, B ; Donati, G ; Cianciolo, G ; Scolari, M.P ; Stefoni, S</creator><creatorcontrib>Faenza, A ; Fuga, G ; Nardo, B ; Donati, G ; Cianciolo, G ; Scolari, M.P ; Stefoni, S</creatorcontrib><description>Abstract Background Metabolic syndrome (MS) includes some risk factors for development of diabetes and cardiovascular disease, obesity (BMI > 30), high triglycerides, low HDL cholesterol, hypertension and impaired glucose tolerance. Following the definition of the Adult Treatment Panel III criteria, a diagnosis of MS was established when 3 or more factors were present. In renal transplan patients MS has been reported to negatively influence both patient and graft survivals. The present study sought to verify the effect of MS among our cases. Methods 298 cadaveric renal transplant recipients operated between January 1, 1996 and December 31, 2001 with absence of diabetes before transplantation, stable renal function 1 year posttransplantation and at least 4 years follow up were retrospectively evaluated from the end of the first post-operative year. Results 50 patients out of 298 (16,7%) had MS at the beginning of the study, including 37 of them with 3 and 13 with 4 risk factors. Only one patient with MS died of cardiovascular disease. Graft failure was observed in 23.5% MS patients versus 9,7% patients without the Syndrome (p:n.s.) Only Creatinine and the incidence of Cardiovascular Diseases at 4 years were statistically higher in MS patients ( P < .001). Conclusions These results suggested that MS is a risk factor for increasing CVD morbidity and decreased graft function, but early treatment of risk factors as soon as they become apparent can limit the adverse effects on patient and graft survival.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2007.07.019</identifier><identifier>PMID: 17692629</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Acute Disease ; Adult ; Biological and medical sciences ; Creatinine - blood ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft Rejection - epidemiology ; Graft Survival ; Humans ; Kidney Transplantation - adverse effects ; Kidney Transplantation - mortality ; Male ; Medical sciences ; Metabolic diseases ; Metabolic Syndrome - epidemiology ; Middle Aged ; Miscellaneous ; Other metabolic disorders ; Retrospective Studies ; Risk Factors ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Survival Analysis ; Tissue, organ and graft immunology ; Treatment Failure</subject><ispartof>Transplantation proceedings, 2007-07, Vol.39 (6), p.1843-1846</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-2090d10788af333569b5c130f8da4e31756d2fb4ae5c6bcedb974c0b0ff462453</citedby><cites>FETCH-LOGICAL-c463t-2090d10788af333569b5c130f8da4e31756d2fb4ae5c6bcedb974c0b0ff462453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041134507008081$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19021161$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17692629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faenza, A</creatorcontrib><creatorcontrib>Fuga, G</creatorcontrib><creatorcontrib>Nardo, B</creatorcontrib><creatorcontrib>Donati, G</creatorcontrib><creatorcontrib>Cianciolo, G</creatorcontrib><creatorcontrib>Scolari, M.P</creatorcontrib><creatorcontrib>Stefoni, S</creatorcontrib><title>Metabolic Syndrome After Kidney Transplantation</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Background Metabolic syndrome (MS) includes some risk factors for development of diabetes and cardiovascular disease, obesity (BMI > 30), high triglycerides, low HDL cholesterol, hypertension and impaired glucose tolerance. Following the definition of the Adult Treatment Panel III criteria, a diagnosis of MS was established when 3 or more factors were present. In renal transplan patients MS has been reported to negatively influence both patient and graft survivals. The present study sought to verify the effect of MS among our cases. Methods 298 cadaveric renal transplant recipients operated between January 1, 1996 and December 31, 2001 with absence of diabetes before transplantation, stable renal function 1 year posttransplantation and at least 4 years follow up were retrospectively evaluated from the end of the first post-operative year. Results 50 patients out of 298 (16,7%) had MS at the beginning of the study, including 37 of them with 3 and 13 with 4 risk factors. Only one patient with MS died of cardiovascular disease. Graft failure was observed in 23.5% MS patients versus 9,7% patients without the Syndrome (p:n.s.) Only Creatinine and the incidence of Cardiovascular Diseases at 4 years were statistically higher in MS patients ( P < .001). Conclusions These results suggested that MS is a risk factor for increasing CVD morbidity and decreased graft function, but early treatment of risk factors as soon as they become apparent can limit the adverse effects on patient and graft survival.</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Creatinine - blood</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Graft Rejection - epidemiology</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney Transplantation - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Other metabolic disorders</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Survival Analysis</subject><subject>Tissue, organ and graft immunology</subject><subject>Treatment Failure</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd9r2zAQx8VoWdOs_8IIg-7N6Z0ky3YfBiHrL9qxh7bPQpZPoMyxM8kp5L-vvISu7GlwIMR97r5332PsC8IcAdXFaj4E08VN6C1RM-cAxXwMrD6wCZaFyLji4ohNACRmKGR-wk5jXEH6cyk-shMsVJWYasIuftBg6r71dva465rQr2m2cAOF2b1vOtrNnv5ItaYbzOD77hM7dqaNdHZ4p-z5-uppeZs9_Ly5Wy4eMiuVGDIOFTQIRVkaJ4TIVVXnFgW4sjGSBBa5arirpaHcqtpSU1eFtFCDc1JxmYsp-7rvm7b8vaU46LWPlto0CPXbqFWJuQIFCbzcgzb0MQZyehP82oSdRtCjXXql39ulR7v0GFil4s8HlW29Trm30oM_CTg_ACZa07rUyPr4l6uAIypM3Pc9R8mTF09BR-upS4v5QHbQTe__b55v_7Sxre98Uv5FO4qrfhu65LpGHbkG_TgeeLwvFAAllCheAee3o6g</recordid><startdate>20070701</startdate><enddate>20070701</enddate><creator>Faenza, A</creator><creator>Fuga, G</creator><creator>Nardo, B</creator><creator>Donati, G</creator><creator>Cianciolo, G</creator><creator>Scolari, M.P</creator><creator>Stefoni, S</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070701</creationdate><title>Metabolic Syndrome After Kidney Transplantation</title><author>Faenza, A ; Fuga, G ; Nardo, B ; Donati, G ; Cianciolo, G ; Scolari, M.P ; Stefoni, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-2090d10788af333569b5c130f8da4e31756d2fb4ae5c6bcedb974c0b0ff462453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Creatinine - blood</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Graft Rejection - epidemiology</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney Transplantation - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Other metabolic disorders</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Survival Analysis</topic><topic>Tissue, organ and graft immunology</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faenza, A</creatorcontrib><creatorcontrib>Fuga, G</creatorcontrib><creatorcontrib>Nardo, B</creatorcontrib><creatorcontrib>Donati, G</creatorcontrib><creatorcontrib>Cianciolo, G</creatorcontrib><creatorcontrib>Scolari, M.P</creatorcontrib><creatorcontrib>Stefoni, S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faenza, A</au><au>Fuga, G</au><au>Nardo, B</au><au>Donati, G</au><au>Cianciolo, G</au><au>Scolari, M.P</au><au>Stefoni, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic Syndrome After Kidney Transplantation</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2007-07-01</date><risdate>2007</risdate><volume>39</volume><issue>6</issue><spage>1843</spage><epage>1846</epage><pages>1843-1846</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Background Metabolic syndrome (MS) includes some risk factors for development of diabetes and cardiovascular disease, obesity (BMI > 30), high triglycerides, low HDL cholesterol, hypertension and impaired glucose tolerance. Following the definition of the Adult Treatment Panel III criteria, a diagnosis of MS was established when 3 or more factors were present. In renal transplan patients MS has been reported to negatively influence both patient and graft survivals. The present study sought to verify the effect of MS among our cases. Methods 298 cadaveric renal transplant recipients operated between January 1, 1996 and December 31, 2001 with absence of diabetes before transplantation, stable renal function 1 year posttransplantation and at least 4 years follow up were retrospectively evaluated from the end of the first post-operative year. Results 50 patients out of 298 (16,7%) had MS at the beginning of the study, including 37 of them with 3 and 13 with 4 risk factors. Only one patient with MS died of cardiovascular disease. Graft failure was observed in 23.5% MS patients versus 9,7% patients without the Syndrome (p:n.s.) Only Creatinine and the incidence of Cardiovascular Diseases at 4 years were statistically higher in MS patients ( P < .001). Conclusions These results suggested that MS is a risk factor for increasing CVD morbidity and decreased graft function, but early treatment of risk factors as soon as they become apparent can limit the adverse effects on patient and graft survival.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>17692629</pmid><doi>10.1016/j.transproceed.2007.07.019</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1345 |
ispartof | Transplantation proceedings, 2007-07, Vol.39 (6), p.1843-1846 |
issn | 0041-1345 1873-2623 |
language | eng |
recordid | cdi_proquest_miscellaneous_68156060 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Acute Disease Adult Biological and medical sciences Creatinine - blood Female Fundamental and applied biological sciences. Psychology Fundamental immunology Graft Rejection - epidemiology Graft Survival Humans Kidney Transplantation - adverse effects Kidney Transplantation - mortality Male Medical sciences Metabolic diseases Metabolic Syndrome - epidemiology Middle Aged Miscellaneous Other metabolic disorders Retrospective Studies Risk Factors Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Survival Analysis Tissue, organ and graft immunology Treatment Failure |
title | Metabolic Syndrome After Kidney Transplantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A11%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20Syndrome%20After%20Kidney%20Transplantation&rft.jtitle=Transplantation%20proceedings&rft.au=Faenza,%20A&rft.date=2007-07-01&rft.volume=39&rft.issue=6&rft.spage=1843&rft.epage=1846&rft.pages=1843-1846&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2007.07.019&rft_dat=%3Cproquest_cross%3E68156060%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68156060&rft_id=info:pmid/17692629&rft_els_id=S0041134507008081&rfr_iscdi=true |